{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:30:20Z","timestamp":1792121420148,"version":"4.4.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004881","name":"Mexican Social Security Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006087","name":"National Autonomous University of Mexico Directorate General of Academic Staff Affairs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006087","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immunology Letters"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.imlet.2026.107150","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:48:04Z","timestamp":1771260484000},"page":"107150","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["PD-L1 expression in cervical cancer tissue is strongly associated with the expression of CD73\/TGF-\u03b21, the percentage of CD8+\/PD-1+ T cells and disease progression"],"prefix":"10.1016","volume":"280","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3705-219X","authenticated-orcid":false,"given":"Mu\u00f1\u00f3z-God\u00ednez","family":"Ricardo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monroy-Garc\u00eda","family":"Alberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1ndez-Cueto \u00c1ngeles","family":"Mar\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garc\u00eda-Rocha","family":"Rosario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4893-530X","authenticated-orcid":false,"given":"Weiss-Steider","family":"Benny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hern\u00e1ndez-Montes","family":"Jorge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don-L\u00f3pez Christian","family":"Azucena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D\u00edaz Ramos","family":"Juan Antonio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9118-8800","authenticated-orcid":false,"given":"P\u00e9rez-Koldenkova","family":"Vadim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5699-8920","authenticated-orcid":false,"given":"Molina-Castillo","family":"Gabriela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-0162","authenticated-orcid":false,"given":"Mora-Garc\u00eda Mar\u00eda","family":"de Lourdes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.imlet.2026.107150_bib0001","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/ijc.35278","article-title":"The GLOBOCAN 2022 cancer estimates: data sources, methods, and a snapshot of the cancer burden worldwide","volume":"156","author":"Filho","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.imlet.2026.107150_bib0002","first-page":"176","volume":"7","author":"Doorbar","year":"2019"},{"key":"10.1016\/j.imlet.2026.107150_bib0003","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/mi.2008.33","article-title":"Evolving immunosuppressive microenvironment during human cervical carcinog\u00e9nesis","volume":"1","author":"Kobayashi","year":"2008","journal-title":"Mucosal Immunol."},{"key":"10.1016\/j.imlet.2026.107150_bib0004","doi-asserted-by":"crossref","first-page":"328rv4","DOI":"10.1126\/scitranslmed.aad7118","article-title":"PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations","volume":"8","author":"Zou","year":"2016","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.imlet.2026.107150_bib0005","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1097\/PGP.0000000000000623","article-title":"PD-L1 expression correlates with young age and CD8+ TIL density in poorly differentiated cervical squamous cell carcinoma","volume":"39","author":"Saglam","year":"2020","journal-title":"Int. J. Gynecol. Pathol."},{"key":"10.1016\/j.imlet.2026.107150_bib0006","article-title":"PD-1\/PD-L1 inhibitors for advanced or metastatic cervical cancer: from bench to bed","volume":"12","author":"Huang","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2026.107150_bib0007","doi-asserted-by":"crossref","first-page":"6341","DOI":"10.1158\/1078-0432.CCR-09-1652","article-title":"Tumor-expressed B7-H1 and B7- DC in relation to PD-1+ T-cell infiltration and survival of patients with cervical carcinoma","volume":"15","author":"Karim","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.imlet.2026.107150_bib0008","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2147\/CMAR.S152232","article-title":"The relationship between the PD-1\/PD-L1 pathway and DNA mismatch repair in cervical cancer and its clinical significance","volume":"10","author":"Yang-Chun","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.imlet.2026.107150_bib0009","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s40425-019-0770-2","article-title":"Mechanisms regulating PD-L1 expression on tumor and immune cells","volume":"7","author":"Chen","year":"2019","journal-title":"Immunother. Cancer"},{"key":"10.1016\/j.imlet.2026.107150_bib0010","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1038\/nature25501","article-title":"TGF\u03b2 attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells","volume":"554","author":"Mariathasan","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.imlet.2026.107150_bib0011","doi-asserted-by":"crossref","first-page":"753","DOI":"10.5306\/wjco.v5.i4.753","article-title":"Role of IL-10 and TGF-beta1 in local immunosuppression in HPV-associated cervical neoplasia","volume":"5","author":"Torres-Poveda","year":"2014","journal-title":"World J. Clin. Oncol."},{"key":"10.1016\/j.imlet.2026.107150_bib0012","doi-asserted-by":"crossref","first-page":"7075","DOI":"10.1007\/s13277-016-5028-8","article-title":"Transforming growth factor-beta1 in carcinogenesis, progression, and therapy in cervical cancer","volume":"37","author":"Zhu","year":"2016","journal-title":"Tumour Biol."},{"key":"10.1016\/j.imlet.2026.107150_bib0013","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cyto.2018.09.018","article-title":"Cervical cancer cells produce TGF-beta1 through the CD73-adenosine pathway and maintain CD73 expression through the autocrine activity of TGF-beta1","volume":"118","author":"Garc\u00eda-Rocha","year":"2019","journal-title":"Cytokine"},{"key":"10.1016\/j.imlet.2026.107150_bib0014","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s11302-006-9003-5","article-title":"The ENTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance","volume":"2","author":"Robson","year":"2006","journal-title":"Purinergic Signal."},{"key":"10.1016\/j.imlet.2026.107150_bib0015","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev.pharmtox.41.1.775","article-title":"Molecular approach to adenosine receptors: receptor-mediated mechanisms of tissue protection","volume":"41","author":"Linden","year":"2001","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.imlet.2026.107150_bib0016","doi-asserted-by":"crossref","first-page":"397","DOI":"10.3390\/ph17030397","article-title":"Adenosine increases the immunosuppressive capacity of cervical cancer cells by increasing PD-L1 expression and TGF-\u03b2 production through its interaction with A2AR\/A2BR","volume":"17","author":"Garc\u00eda-Rocha","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.imlet.2026.107150_bib0017","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1001\/jama.287.16.2114","article-title":"The 2001 Bethesda system: terminology for reporting results of cervical cytology","volume":"287","author":"Solomon","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.imlet.2026.107150_bib0018","doi-asserted-by":"crossref","DOI":"10.1155\/2020\/1678780","article-title":"Detection of CD39 and a highly glycosylated isoform of soluble CD73 in the plasma of patients with cervical cancer: correlation with disease progression","author":"Mu\u00f1\u00f3z-God\u00ednez","year":"2020","journal-title":"Mediators Inflamm."},{"key":"10.1016\/j.imlet.2026.107150_bib0019","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/00003081-196712000-00002","article-title":"Natural history of cervical intraepithelial neoplasia","volume":"10","author":"Richart","year":"1967","journal-title":"Clin. Obstet. Gynecol."},{"key":"10.1016\/j.imlet.2026.107150_bib0020","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12943-022-01569-x","article-title":"Targeting TGF-\u03b2 signal transduction for fibrosis and cancer therapy","volume":"21","author":"Peng","year":"2022","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.imlet.2026.107150_bib0021","first-page":"229","article-title":"A review of cervical cancer: incidence and disparities","volume":"112","author":"Buskwofie","year":"2020","journal-title":"J. Natl. Med. Assoc."},{"key":"10.1016\/j.imlet.2026.107150_bib0022","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ajog.2015.07.022","article-title":"Changing paradigms in the systemic treatment of advanced cervical cancer","volume":"214","author":"Pfaendler","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.imlet.2026.107150_bib0023","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/GCO.0000000000000042","article-title":"Chemotherapy in the treatment of metastatic, persistent, and recurrent cervical cancer","volume":"26","author":"Eskander","year":"2014","journal-title":"Curr. Opin. Obstet. Gynecol."},{"key":"10.1016\/j.imlet.2026.107150_bib0024","doi-asserted-by":"crossref","first-page":"4438","DOI":"10.3390\/cancers13174438","article-title":"Ovarian cancer in the era of immune checkpoint inhibitors: state of the art and future perspectives","volume":"13","author":"Maiorano","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.imlet.2026.107150_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.672386","article-title":"Identifying potential neoantigens for cervical cancer immunotherapy using comprehensive genomic variation profiling of cervical intraepithelial neoplasia and cervical cancer","volume":"11","author":"Bao","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.imlet.2026.107150_bib0026","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.imlet.2026.107150_bib0027","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ygyno.2017.02.027","article-title":"Potential immunotherapy targets in recurrent cervical cancer","volume":"145","author":"Ring","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.imlet.2026.107150_bib0028","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1007\/s11684-018-0674-4","article-title":"PD-1\/PD-L1 blockade in cervical cancer: current studies and perspectives","volume":"13","author":"Wang","year":"2019","journal-title":"Front. Med."},{"key":"10.1016\/j.imlet.2026.107150_bib0029","doi-asserted-by":"crossref","first-page":"3858","DOI":"10.1186\/s13000-017-0631-6","article-title":"Programmed death-ligand 1 (PD-L1) is expressed in a significant number of the uterine cervical carcinomas","volume":"12","author":"Reddy","year":"2017","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.imlet.2026.107150_bib0030","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1038\/modpathol.2016.64","article-title":"Prognostic effect of different PD-L1 expression patterns in squamous cell carcinoma and adenocarcinoma of the cervix","volume":"29","author":"Heeren","year":"2016","journal-title":"Mod. Pathol."},{"issue":"4","key":"10.1016\/j.imlet.2026.107150_bib0031","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/modpathol.2016.221","article-title":"Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer","volume":"30","author":"Enwere","year":"2017","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.imlet.2026.107150_bib0032","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.imlet.2026.107150_bib0033","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1111\/jog.13411","article-title":"Expressions of programmed death (PD)-1 and PD-1 ligand (PDL1) in cervical intraepithelial neoplasia and cervical squamous cell carcinomas are of prognostic value and associated with human papillomavirus status","volume":"43","author":"Yang","year":"2017","journal-title":"J. Obstet. Gynaecol. Res."},{"issue":"7","key":"10.1016\/j.imlet.2026.107150_bib0034","first-page":"615","article-title":"Risk factors for high-risk type human papillomavirus infection among Mexican-American women","volume":"8","author":"Giuliano","year":"1999","journal-title":"Cancer Epid. Biomar. Prev."},{"key":"10.1016\/j.imlet.2026.107150_bib0035","first-page":"113","article-title":"TGF-beta signalling pathway factors in HPV-induced cervical lesions","volume":"69","author":"Iancu","year":"2010","journal-title":"Roum. Arch. Microbiol. Immunol."},{"key":"10.1016\/j.imlet.2026.107150_bib0036","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cells8040320","article-title":"Combined inhibition of TGF-\u03b2 signaling and the PD-L1 immune checkpoint is differentially effective in tumor models","volume":"8","author":"Sow","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.imlet.2026.107150_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.142843","article-title":"Anti-PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC","volume":"7","author":"Tu","year":"2022","journal-title":"JCI Insight"},{"key":"10.1016\/j.imlet.2026.107150_bib0038","article-title":"Bispecific antibody targeting TGF-beta and PD-L1 for synergistic cancer immunotherapy","volume":"14","author":"Li","year":"2023","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.imlet.2026.107150_bib0039","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s13045-021-01045-x","article-title":"The construction, expression, and enhanced anti-tumor activity of YM101: a bispecific antibody simultaneously targeting TGF-\u03b2 and PD-L1","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"12","key":"10.1016\/j.imlet.2026.107150_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005543","article-title":"Anti-TGF-\u03b2\/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triplenegative breast cancer","volume":"10","author":"Yi","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.imlet.2026.107150_bib0041","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s13045-021-01155-6","article-title":"Combine and conquer: manganese synergizing anti-TGF-\u03b2\/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers","volume":"14","author":"Yi","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"424","key":"10.1016\/j.imlet.2026.107150_bib0042","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aan5488","article-title":"Enhanced preclinical antitumor activity of M7824, a bifunctional fusion protein simultaneously targeting PD-L1 and TGF-\u03b2","volume":"10","author":"Lan","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.imlet.2026.107150_bib0043","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004122","article-title":"Colocalized targeting of TGF-\u03b2 and PD-L1 by bintrafusp alfa elicits distinct antitumor responses","volume":"10","author":"Lan","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.imlet.2026.107150_bib0044","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.814169","article-title":"The changing landscape of systemic treatment for cervical cancer: rationale for inhibition of the TGF-\u03b2 and PD-L1 pathways","volume":"12","author":"Birrer","year":"2022","journal-title":"Front. Oncol."}],"container-title":["Immunology Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826000234?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165247826000234?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T04:25:22Z","timestamp":1779942322000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165247826000234"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":44,"alternative-id":["S0165247826000234"],"URL":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107150","relation":{},"ISSN":["0165-2478"],"issn-type":[{"value":"0165-2478","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PD-L1 expression in cervical cancer tissue is strongly associated with the expression of CD73\/TGF-\u03b21, the percentage of CD8+\/PD-1+ T cells and disease progression","name":"articletitle","label":"Article Title"},{"value":"Immunology Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.imlet.2026.107150","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Federation of Immunological Societies.","name":"copyright","label":"Copyright"}],"article-number":"107150"}}